• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于评估嵌合抗原受体T细胞疗法的生物发光急性髓系白血病人源化小鼠模型的开发方案。

Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy.

作者信息

Safont Mireia Mayoral, Leitch Calum, Popa Mihaela, Gjerstad May Eriksen, Caulier Benjamin, Inderberg Else Marit, Wälchli Sébastien, Gelebart Pascal, McCormack Emmet

机构信息

Precision Oncology Research Group, University of Bergen, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway; Kinn Therapeutics, Bergen, Norway.

Precision Oncology Research Group, University of Bergen, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway; Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway.

出版信息

STAR Protoc. 2024 Dec 20;5(4):103522. doi: 10.1016/j.xpro.2024.103522. Epub 2024 Dec 12.

DOI:10.1016/j.xpro.2024.103522
PMID:39673705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11699402/
Abstract

Patient-derived xenograft (PDX) models of acute myeloid leukemia (AML-PDX) offer advantages over cell line models by capturing the complexity and heterogeneity of patient-derived samples. Here, we present a protocol for developing a bioluminescent AML-PDX model in mice to evaluate chimeric antigen receptor (CAR) T cell therapy. We describe steps for transducing, engrafting, expanding, and enriching AML-PDX cells. We then detail procedures for in vitro and in vivo validation of the AML-PDX model for the evaluation of CAR T cell immunotherapy. For complete details on the use and execution of this protocol, please refer to Caulier et al..

摘要

急性髓系白血病患者来源的异种移植（AML-PDX）模型通过捕捉患者来源样本的复杂性和异质性，比细胞系模型具有优势。在此，我们展示了一种在小鼠中建立生物发光AML-PDX模型以评估嵌合抗原受体（CAR）T细胞疗法的方案。我们描述了转导、植入、扩增和富集AML-PDX细胞的步骤。然后，我们详细介绍了用于评估CAR T细胞免疫疗法的AML-PDX模型的体外和体内验证程序。有关本方案使用和执行的完整详细信息，请参阅Caulier等人的文章。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/ccf8089400a9/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/f00d4e737e15/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/6d554d1a163e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/4a63b9f4ee3d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/72589ee4f52d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/a5f86c567fbb/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/ccf8089400a9/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/f00d4e737e15/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/6d554d1a163e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/4a63b9f4ee3d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/72589ee4f52d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/a5f86c567fbb/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95c5/11699402/ccf8089400a9/gr5.jpg

相似文献

1
Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy.用于评估嵌合抗原受体T细胞疗法的生物发光急性髓系白血病人源化小鼠模型的开发方案。
STAR Protoc. 2024 Dec 20;5(4):103522. doi: 10.1016/j.xpro.2024.103522. Epub 2024 Dec 12.
2
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.带有关闭开关的同种异体 FLT3 CAR T 细胞对 AML 具有强大的活性，并可被清除以加速骨髓恢复。
Mol Ther. 2020 Oct 7;28(10):2237-2251. doi: 10.1016/j.ymthe.2020.06.022. Epub 2020 Jun 19.
3
Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia.针对急性髓系白血病免疫逃逸的靶向 CD33 和 CD123 的 Loop33 × 123 CAR-T。
Cancer Immunol Immunother. 2024 Nov 13;74(1):20. doi: 10.1007/s00262-024-03847-7.
4
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.CD33 导向嵌合抗原受体 T 细胞免疫疗法治疗急性髓系白血病的系统临床前评价确定了优化的构建设计。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-003149.
5
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.通过适配器 CAR-T 细胞（AdCAR-T）进行合理的组合靶向可防止急性髓系白血病中的抗原逃逸。
Leukemia. 2024 Oct;38(10):2183-2195. doi: 10.1038/s41375-024-02351-2. Epub 2024 Aug 3.
6
Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.嵌合抗原受体靶向 C 型凝集素样分子-1 治疗人类急性髓系白血病的研究进展。
Int J Mol Sci. 2017 Oct 27;18(11):2259. doi: 10.3390/ijms18112259.
7
Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.抗人 CD117 CAR T 细胞能有效清除表达 CD117 的健康和恶性造血细胞。
Leukemia. 2020 Oct;34(10):2688-2703. doi: 10.1038/s41375-020-0818-9. Epub 2020 May 1.
8
Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.使用嵌合抗原受体T细胞靶向肿瘤抗原5T4治疗急性髓系白血病
Mol Cancer Ther. 2025 Jan 2;24(1):93-104. doi: 10.1158/1535-7163.MCT-24-0052.
9
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.嵌合抗原受体 T 细胞治疗 C 型凝集素样分子 1 靶向的急性髓系白血病。
Mol Ther. 2017 Sep 6;25(9):2202-2213. doi: 10.1016/j.ymthe.2017.05.024. Epub 2017 Jul 1.
10
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.B7-H3 特异性嵌合抗原受体 T 细胞治疗急性髓系白血病的临床前评估。
Clin Cancer Res. 2021 Jun 1;27(11):3141-3153. doi: 10.1158/1078-0432.CCR-20-2540. Epub 2021 Feb 2.

本文引用的文献

1
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.CD37 是治疗急性髓系白血病的安全嵌合抗原受体靶标。
Cell Rep Med. 2024 Jun 18;5(6):101572. doi: 10.1016/j.xcrm.2024.101572. Epub 2024 May 15.
2
Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice.在下一代人源化小鼠中模拟肿瘤微环境与癌症免疫疗法
Cancers (Basel). 2023 May 30;15(11):2989. doi: 10.3390/cancers15112989.
3
Patient-derived xenograft models in cancer therapy: technologies and applications.癌症治疗中的患者来源异种移植模型：技术与应用。
Signal Transduct Target Ther. 2023 Apr 12;8(1):160. doi: 10.1038/s41392-023-01419-2.
4
Humanized mouse models for immuno-oncology research.用于肿瘤免疫研究的人源化小鼠模型。
Nat Rev Clin Oncol. 2023 Mar;20(3):192-206. doi: 10.1038/s41571-022-00721-2. Epub 2023 Jan 12.
5
Towards precision oncology with patient-derived xenografts.朝着基于患者来源异种移植的精准肿瘤学发展。
Nat Rev Clin Oncol. 2022 Nov;19(11):719-732. doi: 10.1038/s41571-022-00682-6. Epub 2022 Sep 23.
6
Bioluminescence Imaging for Evaluation of Antitumor Effect In Vitro and In Vivo in Mice Xenografted Tumor Models.生物发光成像用于评估小鼠异种移植瘤模型的体外和体内抗肿瘤效果
Methods Mol Biol. 2022;2524:307-315. doi: 10.1007/978-1-0716-2453-1_24.
7
Patient-derived xenograft (PDX) models, applications and challenges in cancer research.患者来源异种移植 (PDX) 模型在癌症研究中的应用及挑战。
J Transl Med. 2022 May 10;20(1):206. doi: 10.1186/s12967-022-03405-8.
8
Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies.用于推进基于先天淋巴细胞的癌症免疫疗法的人源化小鼠模型。
Front Immunol. 2021 Apr 22;12:648580. doi: 10.3389/fimmu.2021.648580. eCollection 2021.
9
Patient-derived xenografts as compatible models for precision oncology.患者来源的异种移植作为精准肿瘤学的兼容模型。
Lab Anim Res. 2020 May 20;36:14. doi: 10.1186/s42826-020-00045-1. eCollection 2020.
10
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.肿瘤内异质性：治疗抵抗的罗塞塔石碑。
Cancer Cell. 2020 Apr 13;37(4):471-484. doi: 10.1016/j.ccell.2020.03.007.